What are the fundraising trends in the MedTech market?
In our updated market reports, you will find everything you need
SUMMARY
We analyzed publicly disclosed equity rounds raised by pure-play MedTech companies between January 2024 and July 2026. The dataset keeps disclosed rounds of $300K or more and excludes grants, debt-only financings, M&A, mixed rounds without a clean equity amount, consumer wellness wearables, pharma, biotech, broad healthcare IT, and companies where MedTech is not the core business.
The resulting sample shows a MedTech market that is active but highly selective. Full-year 2024 produced 36 deals and about $2.41B of capital, full-year 2025 produced 36 deals and about $2.51B, and year-to-date 2026 has already produced 40 deals and about $1.54B.
The freshest signal is that the MedTech market is funding more companies but with smaller checks. Year-to-date 2026 deal count is more than double the comparable 2025 period, rising from 17 to 40 deals, while capital fell from about $1.83B to about $1.54B.
Round size compression is the clearest change. The year-to-date 2026 median round is $20M, down from $35M in the comparable 2025 period and $60M in the comparable 2024 period, which means the typical MedTech company is raising less even as more companies are getting financed.
The MedTech market remains validation-led. Late-stage companies captured 84.6% of capital in 2024, 92.3% in 2025, and 77.8% so far in 2026, showing that the largest checks still go to companies with clinical, regulatory, commercial, or strategic proof.
Implantable Devices are the strongest capital category across the dataset. The category led full-year 2024 with 40.4% of capital, full-year 2025 with 35.0%, and year-to-date 2026 with 34.3%, confirming that investors continue to reward device categories with clear clinical endpoints and defensible regulatory pathways.
The 2026 MedTech market is broader by category than the earlier periods. Medical Devices, Diagnostic Devices, Implantable Devices, Surgical Tools, Connected Medical Devices, Device Data Platforms, and Digital Therapeutics all have multiple deals, but the dollars are still concentrated in Implantable Devices, Medical Devices, and selected therapeutic software or infrastructure platforms.
North America remains the dominant scale-financing region. It captured 76.5% of full-year 2024 capital, 58.3% of full-year 2025 capital, and 69.1% of year-to-date 2026 capital, while Europe is consistently important by deal count but usually raises smaller median rounds.
First financings are scarce compared with 2024. New-company rounds were 36.1% of deals in 2024, but only 5.6% in 2025 and 7.5% so far in 2026, which means the MedTech market is open to new startups but is not primarily a startup-formation market.
The main interpretation is that MedTech fundraising is healthier by activity than by headline dollars. Investors are not leaving the MedTech market; they are spreading more modest checks across more companies while reserving scale capital for clinically credible, regulated, and strategically relevant assets.
Is more or less capital going into the MedTech market?
Less capital is going into the MedTech market so far in 2026 than over the comparable period in 2025, but the decline is not a simple demand-collapse story. Year-to-date 2026 MedTech funding reached about $1.54B across 40 deals, compared with about $1.83B across 17 deals over the same window in 2025.
That means capital is down by roughly 16%, while the number of funded companies is up sharply. The MedTech market is therefore not freezing; it is repricing around smaller rounds and broader participation.
The full-year comparison between 2024 and 2025 was much flatter. Full-year 2025 reached about $2.51B across 36 deals, compared with about $2.41B across the same number of deals in 2024, so 2025 was not a structural acceleration year.
The practical takeaway is that 2025 was inflated by trophy financings such as Neuralink and Neko Health, while 2026 has fewer ultra-large rounds. The MedTech market has plenty of activity, but the headline capital pool is less dependent on $100M-plus financings than it was in early 2025.
Is MedTech funding driven by more deals or larger rounds?
MedTech funding is currently being driven by more deals, not larger rounds. So far in 2026, the MedTech market has produced 40 qualifying deals through July, compared with 17 over the comparable 2025 period, but total capital is lower.
The average round size explains the shift. The year-to-date average MedTech round fell from about $108M in 2025 to about $38M in 2026, while the median round fell from $35M to $20M.
The same pattern appears when comparing full-year 2025 with full-year 2024. Average round size rose slightly in 2025, but the median round fell from about $52M to about $26M, which confirms that 2025 was outlier-driven rather than broadly stronger for the typical company.
The honest interpretation is that the MedTech market has moved from large checks for a smaller set of companies toward more checks, but smaller checks. This is a broader market by count and a more disciplined market by round size.
Is MedTech capital moving toward later-stage or earlier-stage companies?
MedTech capital is still moving toward later-stage companies, even though year-to-date 2026 has a healthier early-stage deal-count signal than 2025. Seed and Series A deals account for 40% of 2026 deal count, but only 14.6% of capital.
Late-stage companies remain the dollar-weighted center of the MedTech market. Series B and later rounds captured 84.6% of capital in 2024, 92.3% in 2025, and 77.8% so far in 2026.
Series C is especially important in the current period. It accounts for about $692M, or 45% of all 2026 year-to-date capital, which confirms that investors are still writing the largest checks after major technical, clinical, regulatory, or commercial milestones have been reached.
The practical takeaway is that early-stage activity has recovered, but the MedTech market is not early-stage-led. Investors are willing to keep more companies alive, but they reserve scale capital for de-risked assets.
Is the MedTech market maturing or still experimental?
The MedTech market is maturing, not merely experimental. The strongest evidence is that late-stage companies captured the overwhelming majority of capital in every measured period, including 77.8% so far in 2026.
The category mix also points to a mature center of gravity. Implantable Devices, Surgical Tools, and Medical Devices are regulated, device-heavy categories that usually require clinical evidence, reimbursement logic, physician adoption, and long development timelines.
That does not mean the MedTech market has no experimental edge. Device Data Platforms rose from $16M in 2024 to $39M in 2025 and $135M so far in 2026, while Digital Therapeutics reappeared strongly in 2026 with $175M across three deals.
The best interpretation is that the MedTech market is mature at the center and experimental at the edges. Investors still underwrite the market with device-investor discipline, but they are testing software infrastructure, AI-enabled diagnostics, and regulated therapeutic software around that core.
Are new startups still entering the MedTech market?
New startups are still entering the MedTech market, but new-company formation is not the main story. First financings are only 7.5% of year-to-date 2026 deals and 5.3% of capital.
That is an improvement from full-year 2025, when first financings were only 5.6% of deals and 0.3% of capital. But it is far below 2024, when first financings represented 36.1% of deals and 14.0% of capital.
The clearest 2026 example is Spiro Medical, which raised a $67M Series A first financing for pulmonary neuromodulation. That shows a new MedTech company can still raise aggressively when the clinical need, syndicate quality, and device pathway are strong.
The practical rule is that the MedTech market is not closed to new startups, but the bar is high. Investors are not broadly funding unproven device concepts; they are backing new companies that already look unusually validated from day one.
Are more investors entering the MedTech market?
More investors appear to be entering or re-entering the MedTech market in 2026, but the signal should be read carefully because investor counts depend on how fully syndicates are disclosed. Year-to-date 2026 has approximately 107 disclosed investors and about 45 tier-1 investors, compared with approximately 55 disclosed investors and about 28 tier-1 investors over the comparable 2025 period.
Some of that increase simply reflects more deals. The MedTech market has 40 year-to-date 2026 deals versus 17 over the same period in 2025, so a larger investor count is expected.
The more useful signal is that the investor base is distributed rather than controlled by one tight club. Mérieux Equity Partners, Atlantic Bridge, Santé Ventures, and Ajax Health each appear more than once in the 2026 dataset, but no investor dominates the market.
This suggests the MedTech market is attracting broader capital participation, while still depending on specialist conviction for the largest rounds. The headcount of investors is rising, but marquee syndicate quality still matters more than raw investor breadth.
Are top investors getting more or less active in MedTech?
Top investors are getting less individually dominant in the MedTech market, even as the total pool of quality investors is broader. In 2024, Ally Bridge Group appeared in four deals and Intuitive Ventures appeared in three, while several other investors appeared twice.
In 2025, Lightspeed Venture Partners led the repeat list with three deals, while Gilde Healthcare, Accelmed Partners, Invest-NL, the European Innovation Council, Cleveland Clinic, JobsOhio Growth Capital Fund, and QIA-related capital appeared more than once.
So far in 2026, the repeat-investor signal is flatter. Mérieux Equity Partners, Atlantic Bridge, Santé Ventures, and Ajax Health each appear twice, but there is no single fund that defines the year.
The honest interpretation is that MedTech has a broad syndicate ecosystem rather than a single dominant investor cluster. Repeat participation matters, but the largest rounds are still company-specific conviction events, not proof that one investor group is controlling the category.
Which MedTech subcategories are gaining momentum?
Device Data Platforms and Digital Therapeutics are the MedTech subcategories gaining the clearest momentum in 2026. Device Data Platforms grew from $16M in 2024 to $39M in 2025 and $135M so far in 2026.
That growth is not just software hype. The funded companies sit close to MedTech workflows, including clinical trial data, regulatory quality systems, commercialization intelligence, and device-market infrastructure.
Digital Therapeutics also returned meaningfully in 2026. Cognito Therapeutics, Click Therapeutics, and Sidekick Health together account for $175M, giving the category 11.4% of year-to-date capital after it was almost absent in 2024 and not represented in the 2025 category split.
Implantable Devices are not newly gaining momentum because they were already strong, but they remain the anchor category. The category has led capital in every measured period and still has the highest 2026 capital-share-to-deal-share ratio at 1.96.
Which MedTech subcategories are losing momentum?
Connected Medical Devices and broad Diagnostic Devices are losing capital intensity in the MedTech market, even where deal activity remains present. Connected Medical Devices fell from 10.6% of 2024 capital and 10.2% of 2025 capital to 5.1% so far in 2026.
Diagnostic Devices tell a different but related story. They account for 20% of 2026 deal count, but only 5.7% of capital, which means many diagnostic companies are getting funded but at relatively modest scale.
Hospital Equipment is also absent from the year-to-date 2026 screened dataset after taking 7.3% of full-year 2025 capital. That absence is meaningful because it shows investors are currently favoring proprietary devices, implants, surgical systems, and software layers over heavier hospital-budget equipment models.
The practical takeaway is that category visibility is not the same as funding strength. Diagnostics and connected monitoring can generate many plausible companies, but the largest MedTech checks still require a direct link to clinical decisions, therapeutic workflows, or reimbursable procedure pathways.
Which regions are gaining momentum in MedTech funding?
Asia-Pacific, the Middle East, and Africa are gaining visibility in MedTech funding, although from very different bases. Asia-Pacific moved from no comparable year-to-date 2025 deals to three year-to-date 2026 deals and about $159M of capital.
The Asia-Pacific signal is driven by Biobeat, Surgerii Robotics, and MARS Bioimaging. That is not yet a broad ecosystem signal, but it does show that APAC-origin MedTech companies can appear in a strict public-source, equity-only dataset when the rounds are large enough and clearly disclosed.
The Middle East remains small by capital in 2026, with two deals and about $33M, but it continues to appear across the dataset after a stronger 2025. Africa also appears in 2026 through AI Diagnostics, which is small in dollar terms but important for regional visibility.
The broader read is that MedTech company formation is becoming more geographically visible. The largest scale checks still cluster in North America, but the map of qualifying disclosed deals is wider in 2026 than it was in the comparable 2025 period.
Which regions are losing momentum in MedTech funding?
Europe is losing some capital intensity in MedTech funding, even though it remains a strong deal-count region. Europe captured 34.2% of full-year 2025 capital and 31.7% of comparable year-to-date 2025 capital, but only 18.1% of year-to-date 2026 capital.
That does not mean Europe is disappearing. Europe accounts for 12 of 40 year-to-date 2026 deals, or 30% of the total, which is close to its full-year 2025 deal share.
The issue is check size. Europe’s median year-to-date 2026 round is about $16.5M, compared with $27.5M in North America and $50M in Asia-Pacific. The region is generating many credible MedTech financings, but fewer of the largest scale rounds.
The practical interpretation is that Europe remains healthy at the formation and mid-stage layer, but North America remains the stronger scale-financing environment. Europe is not losing relevance; it is losing dollar share.
Is MedTech becoming more global or regionally concentrated?
The MedTech market is becoming more global by deal presence, but it remains regionally concentrated by capital. Year-to-date 2026 includes deals from North America, Europe, Asia-Pacific, the Middle East, and Africa, which is broader than the comparable 2025 period.
Capital remains much more concentrated. North America accounts for 55% of year-to-date 2026 deals but 69.1% of capital, which means it still over-indexes on large rounds.
Europe shows the opposite pattern, with 30% of deals and 18.1% of capital. Africa appears with one deal but only 0.3% of capital, which confirms that global visibility does not yet equal global scale financing.
The best interpretation is that the MedTech market is globalizing at the company-disclosure layer and concentrating at the capital layer. More regions are visible, but North America remains the main home for large late-stage checks.
Is MedTech capital moving toward proven winners or new opportunities?
MedTech capital is moving toward proven winners, although 2026 has more room for new opportunities than 2025 did. First financings were 36.1% of deals in 2024, but only 5.6% in 2025 and 7.5% so far in 2026.
Capital share makes the point even clearer. First financings captured 14.0% of 2024 capital, 0.3% of 2025 capital, and 5.3% of year-to-date 2026 capital.
The stage mix says the same thing. Late-stage companies captured 92.3% of 2025 capital and 77.8% of 2026 year-to-date capital, while Series C alone accounts for 45% of 2026 capital.
The practical takeaway is that the MedTech market is selectively open to new opportunities, but the money is still flowing toward proven winners. The default investor posture is show proof, then scale.
Is the MedTech market becoming winner-takes-most?
The MedTech market is not fully winner-takes-most, but it is winner-takes-a-lot. In full-year 2025, the largest deal captured 25.9% of all capital, the top three captured 46.1%, and the top ten captured 78.2%.
Concentration has eased in 2026 but remains meaningful. The top deal accounts for 15.0% of year-to-date capital, the top three for 28.3%, the top five for 40.4%, and the top ten for 64.9%.
Full-year 2024 was less extreme than 2025, with the top ten deals capturing 58.0% of capital. So 2026 is less concentrated than 2025, but still more concentrated than 2024 by top-ten share.
The better phrasing is that the MedTech market is winner-takes-most at the capital layer, but not at the deal layer. Many companies can raise something, but only a smaller group can raise the scale capital needed for pivotal trials, commercialization, or category leadership.
Is the next wave of MedTech winners becoming visible?
The next wave of MedTech winners is becoming visible, but it is visible through validation density rather than raw deal count. The strongest candidates sit in Implantable Devices, selected Surgical Tools, Digital Therapeutics, Device Data Platforms, and commercially relevant Medical Devices.
Implantable Devices remain the clearest winner pool. The category captures 34.3% of year-to-date 2026 capital while representing only 17.5% of deals, with companies such as Science Corporation, GT Medical Technologies, UroMems, Spiro Medical, FineHeart, and CroíValve fitting the pattern.
Device Data Platforms are also becoming visible as a next-wave infrastructure category. AcuityMD, Flywheel, Flinn.ai, and MedScout show that software can count as MedTech when it sits close to device commercialization, regulatory workflows, clinical trials, or market intelligence.
The next winners are not simply companies with AI or connected-device positioning. The likely winners are companies with device-like proof, clinical endpoints, strategic relevance, and a path through regulation, reimbursement, or provider adoption.
Is the MedTech funding landscape fragmenting or consolidating?
The MedTech funding landscape is fragmenting by deal count and consolidating by capital allocation. So far in 2026, the MedTech market has more deals, more disclosed investors, more active categories, and more visible geographies than the comparable 2025 period.
The deal-count side looks fragmented. Medical Devices, Diagnostic Devices, Implantable Devices, Surgical Tools, Connected Medical Devices, Device Data Platforms, and Digital Therapeutics all have multiple 2026 deals.
The capital side looks consolidated. The top ten year-to-date 2026 deals capture 64.9% of capital, late-stage companies capture 77.8%, North America captures 69.1%, and Implantable Devices alone capture 34.3%.
So the MedTech market is bifurcating. More companies are getting funded, but fewer companies are commanding large checks, which is a classic sign of a mature, selective market.
Where is investor attention shifting in MedTech?
Investor attention in the MedTech market is shifting toward clinically validated scale assets, MedTech infrastructure software, AI-enabled diagnostic workflows, and selective digital therapeutics. The clearest category-level shift is Device Data Platforms, which increased from $16M in 2024 to $135M so far in 2026.
That does not mean investors are abandoning the traditional device core. Implantable Devices remain the leading capital category in 2024, 2025, and 2026, which confirms that device-mediated clinical intervention still anchors the MedTech market.
The new attention sits around the core. Investors are funding tools that help MedTech companies run clinical trials, manage regulatory workflows, commercialize devices, analyze imaging, and deliver regulated therapeutic software.
The real shift is not from devices to software. It is from standalone device bets toward device-centered ecosystems, where regulated products, clinical data, workflow software, and strategic commercialization paths reinforce each other.
INSIGHTS
The insights below come from reviewing publicly disclosed equity rounds in the MedTech market across full-year 2024, full-year 2025, and year-to-date 2026 through July.
- The MedTech market should be read through both deal count and capital intensity. Year-to-date 2026 has more than twice as many deals as the comparable 2025 period, but less capital, which means activity is broadening while round sizes are compressing.
- Average round size is a poor standalone measure in MedTech. In 2025, the average round was about $70M while the median was only about $26M, because large outliers pulled the average far above the typical financing.
- Excluding rounds above $50M changes the market picture dramatically. Full-year 2025 capital falls from about $2.51B to about $497M when those rounds are removed, which means the ordinary financing market was only about one-fifth of the headline total.
- The MedTech market is proof-led rather than seed-led. Late-stage rounds captured 84.6% of 2024 capital, 92.3% of 2025 capital, and 77.8% of 2026 year-to-date capital, so investors are mostly funding companies that have already reduced clinical, regulatory, or commercial uncertainty.
- First financings are a useful stress test for new-company formation. The collapse from 36.1% of deals in 2024 to 5.6% in 2025 and 7.5% so far in 2026 shows that the market has shifted away from broad startup creation toward follow-on support.
- Implantable Devices are the most consistent dollar-weighted winner. The category led capital in every measured period, showing that investors are willing to fund invasive technologies when the endpoint is large, measurable, and clinically important.
- Surgical Tools remain active, but they do not always punch above their deal-count weight. The category produces steady deal flow, but the largest checks usually go to companies with pivotal-trial, commercialization, or strategic-acquirer relevance.
- Device Data Platforms are becoming a serious MedTech infrastructure category. The growth from $16M in 2024 to $135M so far in 2026 suggests investors increasingly value the software layer around trials, regulatory workflows, commercialization, and device-market intelligence.
- Digital Therapeutics are not broadly back; they are selectively back. The 2026 rounds show investor appetite for clinical-grade treatment platforms, pharma-linked models, and regulated disease-management software, not generic wellness apps.
- Diagnostic Devices have high deal visibility but lower capital intensity. In 2026, they account for 20% of deals but only 5.7% of capital, which means investors are testing many diagnostic concepts while reserving larger checks for more de-risked clinical pathways.
- Connected Medical Devices need a concrete therapeutic workflow to raise meaningful capital. The strongest connected-device rounds are tied to heart failure, insulin delivery, respiratory monitoring, or other clearly defined medical use cases.
- North America remains the scale-financing center of the MedTech market. Other regions are increasingly visible by deal count, but North America still captures the largest share of capital and the most consistent late-stage check flow.
- Europe is a strong formation and mid-stage market, not a weak market. Its 2026 capital share is lower than its deal share, which points to smaller round sizes rather than lack of MedTech activity.
- Asia-Pacific’s 2026 visibility is meaningful but still fragile. A few sizeable rounds can materially change the region’s apparent strength, so APAC should be evaluated company by company rather than through aggregate totals alone.
- Investor breadth is rising, but repeat dominance is limited. The 2026 dataset includes more than 100 disclosed investors, yet only a handful appear more than once, which means the market is broad but not controlled by a small specialist cartel.
- The bottom half of deals captures a small share of capital in every period. That makes the long tail important for category formation, but not for dollar-weighted market direction.
- The best validation signal is not whether a company says it is AI-enabled or digital. The stronger signal is proximity to a regulated clinical product, a pivotal trial, an FDA or CE pathway, a hospital workflow, or a reimbursable procedure.
- Category labels alone do not predict funding intensity. A diagnostic-device company can raise a small seed or a large growth round; maturity, evidence depth, and clinical urgency explain more than the label.
- The MedTech market is broadening around the core, not replacing the core. Software, data platforms, and digital therapeutics are gaining attention, but the largest dollars still revolve around regulated devices, implants, and procedure-linked interventions.
- The strongest reusable screening rule is simple: MedTech capital scales when regulated product specificity, a large specialist market, and credible syndicate or strategic validation overlap. Deals missing one of those signals usually stay smaller.
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this MedTech funding tracker by reviewing publicly disclosed equity rounds raised by pure-play MedTech companies between January 2024 and July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to medical devices, diagnostic devices, surgical tools, connected medical devices, hospital equipment, implantable devices, digital therapeutics, or device data platforms used to diagnose, monitor, or treat patients.
We applied four main filters to build the dataset. First, we included equity rounds only, so grants, debt-only financings, structured credit facilities, IPOs, acquisitions, SPAC transactions, and business combinations were excluded unless the raw data explicitly isolated a qualifying equity round. Second, we only counted rounds with a disclosed value of at least $300K. Third, we kept only pure-play MedTech companies under the 80% rule. Fourth, every included deal had to be confirmed by a direct company announcement, press release, tier-1 media report, specialist industry source, investor announcement, or relevant regional publication.
We also excluded adjacent cases that would distort the MedTech market view, including consumer wellness wearables, pharma and biotech therapeutics, broad care-delivery software, generic healthcare IT, and mixed debt-equity rounds where the equity portion could not be isolated. Undisclosed-amount rounds were excluded because including them would distort dollar-based metrics such as average round size, median round size, category share, regional share, and concentration ratios.
The final dataset is therefore a public-source funding tracker, not a paid private-market database export. It is designed to make MedTech funding direction, category concentration, regional distribution, stage mix, and investor behavior comparable across full-year 2024, full-year 2025, and year-to-date 2026.
Related blog posts
- The most heavily funded startups in the MedTech market
- The highest-valued startups in the MedTech market
- What does funding activity look like in the MedTech market?
